Skip to main content
. Author manuscript; available in PMC: 2017 Jan 15.
Published in final edited form as: J Immunol. 2015 Dec 9;196(2):915–923. doi: 10.4049/jimmunol.1500729

Figure 2. DFMO adminstration enhances tumor-infiltrating T cell immunity.

Figure 2

(A) Representative flow cytometric analysis of tumor-infiltrating CD8+TCRVβ+ T cells (5 mice per group). (B) Percent CD8+TCRVβ+ cells and (C) absolute number of gp100-specific tetramer+CD8+TCRVβ+ cells per 106 cells in tumor infiltrates (5 mice per group). (D) Percent IFN-γ secreting CD3+CD8+ T cells in tumor infiltrates. Cells were collected from B16F10-bearing DFMO treated or control mice 14 days after tumor inoculation (5 mice per group). Data (mean ± SEM) are representative of 3 independent experiments. *, p< 0.05.